Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Goetz

Showing results (321-330 of 397) with videos related to

Pageof 40
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2021
Patient-Derived Xenograft Engraftment and Breast Cancer Outcomes in a Prospective Neoadjuvant Study (BEAUTY)Judy C Boughey, Vera J Suman, Jia Yu, et al.
Clinical Pharmacology and Therapeutics|January 17, 2019
Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2Tanda M Dudenkov, Duan Liu, Junmei Cairns, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2024
Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective TrialTufia C Haddad, Vera J Suman, Karthik V Giridhar, et al.
Breast Cancer Research and Treatment|January 3, 2021
A clinical calculator to predict disease outcomes in women with triple-negative breast cancerMei-Yin C Polley, Roberto A Leon-Ferre, Samuel Leung, et al.
NAR Cancer|June 23, 2022
Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy responseKevin J Thompson, Roberto A Leon-Ferre, Jason P Sinnwell, et al.
The Journal of Clinical Investigation|May 1, 2018
DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabineJia Yu, Bo Qin, Ann M Moyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 10, 2024
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3M P Goetz, M Toi, J Huober, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2020
Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORxLynne I Wagner, Robert J Gray, Joseph A Sparano, et al.
The Lancet. Oncology|December 9, 2022
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trialStephen R D Johnston, Masakazu Toi, Joyce O'Shaughnessy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2024
Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast CancerMariana Chavez-MacGregor, Jieling Miao, Lajos Pusztai, et al.
Pageof 40

Showing results (321-330 of 397) with videos related to

Sort By:
Pageof 40
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2021
Patient-Derived Xenograft Engraftment and Breast Cancer Outcomes in a Prospective Neoadjuvant Study (BEAUTY)Judy C Boughey, Vera J Suman, Jia Yu, et al.
Clinical Pharmacology and Therapeutics|January 17, 2019
Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2Tanda M Dudenkov, Duan Liu, Junmei Cairns, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2024
Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective TrialTufia C Haddad, Vera J Suman, Karthik V Giridhar, et al.
Breast Cancer Research and Treatment|January 3, 2021
A clinical calculator to predict disease outcomes in women with triple-negative breast cancerMei-Yin C Polley, Roberto A Leon-Ferre, Samuel Leung, et al.
NAR Cancer|June 23, 2022
Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy responseKevin J Thompson, Roberto A Leon-Ferre, Jason P Sinnwell, et al.
The Journal of Clinical Investigation|May 1, 2018
DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabineJia Yu, Bo Qin, Ann M Moyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 10, 2024
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3M P Goetz, M Toi, J Huober, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2020
Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORxLynne I Wagner, Robert J Gray, Joseph A Sparano, et al.
The Lancet. Oncology|December 9, 2022
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trialStephen R D Johnston, Masakazu Toi, Joyce O'Shaughnessy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2024
Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast CancerMariana Chavez-MacGregor, Jieling Miao, Lajos Pusztai, et al.
Pageof 40